BRPI0907502A2 - pelo menos um entidade química, composição, e, métodos para tratar um paciente tendo uma condição, para aumentar a função ou atividade do músculo esquelético, para aumentar a eficiência do músculo esquelético, parab aumentar o tempo da fadiga de fibra muscular esquelética rápida, para sensibilizar uma fibra muscular esquelética rápida para produzir força em resposta a baixas concentreações de íons cálcio e para aumentar o tempo de fadiga muscular esquelética - Google Patents
pelo menos um entidade química, composição, e, métodos para tratar um paciente tendo uma condição, para aumentar a função ou atividade do músculo esquelético, para aumentar a eficiência do músculo esquelético, parab aumentar o tempo da fadiga de fibra muscular esquelética rápida, para sensibilizar uma fibra muscular esquelética rápida para produzir força em resposta a baixas concentreações de íons cálcio e para aumentar o tempo de fadiga muscular esqueléticaInfo
- Publication number
- BRPI0907502A2 BRPI0907502A2 BRPI0907502A BRPI0907502A BRPI0907502A2 BR PI0907502 A2 BRPI0907502 A2 BR PI0907502A2 BR PI0907502 A BRPI0907502 A BR PI0907502A BR PI0907502 A BRPI0907502 A BR PI0907502A BR PI0907502 A2 BRPI0907502 A2 BR PI0907502A2
- Authority
- BR
- Brazil
- Prior art keywords
- skeletal muscle
- skeletal
- fatigue
- enhancing
- time
- Prior art date
Links
- 210000002027 skeletal muscle Anatomy 0.000 title abstract 8
- 230000002708 enhancing effect Effects 0.000 title abstract 4
- 210000001087 myotubule Anatomy 0.000 title abstract 4
- 206010049565 Muscle fatigue Diseases 0.000 title abstract 3
- 150000005829 chemical entities Chemical class 0.000 title abstract 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 title abstract 2
- 229910001424 calcium ion Inorganic materials 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 230000004220 muscle function Effects 0.000 title abstract 2
- 210000003205 muscle Anatomy 0.000 abstract 2
- 102000007469 Actins Human genes 0.000 abstract 1
- 108010085238 Actins Proteins 0.000 abstract 1
- 206010003694 Atrophy Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 102000003505 Myosin Human genes 0.000 abstract 1
- 108060008487 Myosin Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 102000005937 Tropomyosin Human genes 0.000 abstract 1
- 108010030743 Tropomyosin Proteins 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000037444 atrophy Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000030175 lameness Diseases 0.000 abstract 1
- 208000018360 neuromuscular disease Diseases 0.000 abstract 1
- 210000002235 sarcomere Anatomy 0.000 abstract 1
- 230000001235 sensitizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2606708P | 2008-02-04 | 2008-02-04 | |
| PCT/US2009/000686 WO2009099594A1 (en) | 2008-02-04 | 2009-02-02 | Certain chemical entities, compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0907502A2 true BRPI0907502A2 (pt) | 2019-01-15 |
Family
ID=40952391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0907502A BRPI0907502A2 (pt) | 2008-02-04 | 2009-02-02 | pelo menos um entidade química, composição, e, métodos para tratar um paciente tendo uma condição, para aumentar a função ou atividade do músculo esquelético, para aumentar a eficiência do músculo esquelético, parab aumentar o tempo da fadiga de fibra muscular esquelética rápida, para sensibilizar uma fibra muscular esquelética rápida para produzir força em resposta a baixas concentreações de íons cálcio e para aumentar o tempo de fadiga muscular esquelética |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7989469B2 (enExample) |
| EP (1) | EP2244711A4 (enExample) |
| JP (1) | JP2011510985A (enExample) |
| KR (1) | KR20100119773A (enExample) |
| CN (1) | CN101983061A (enExample) |
| AR (1) | AR072242A1 (enExample) |
| AU (1) | AU2009210787A1 (enExample) |
| BR (1) | BRPI0907502A2 (enExample) |
| CA (1) | CA2713864A1 (enExample) |
| CL (1) | CL2009000246A1 (enExample) |
| CO (1) | CO6290673A2 (enExample) |
| EA (1) | EA201001224A1 (enExample) |
| EC (2) | ECSP10010430A (enExample) |
| IL (1) | IL207367A0 (enExample) |
| MX (1) | MX2010008518A (enExample) |
| TW (1) | TW200946524A (enExample) |
| WO (1) | WO2009099594A1 (enExample) |
| ZA (1) | ZA201005780B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| MX2010008518A (es) * | 2008-02-04 | 2010-11-10 | Cytokinetics Inc | Ciertas entidades quimicas, composiciones y metodos. |
| CN102127070A (zh) * | 2010-01-15 | 2011-07-20 | 山东轩竹医药科技有限公司 | 吡啶并环衍生物 |
| US8927572B2 (en) | 2011-07-09 | 2015-01-06 | Xuanzhu Pharma Co., Ltd. | Crystal form I of salt of a dipeptidyl peptidase-IV inhibitor and preparation method and use thereof |
| WO2013010015A2 (en) | 2011-07-13 | 2013-01-17 | Cytokinetics, Inc. | Combination als therapy |
| CN104395458A (zh) * | 2012-04-11 | 2015-03-04 | 赛特凯恩蒂克公司 | 改善对骨骼肌疲劳的抵抗力 |
| EP3137622B1 (en) | 2014-04-29 | 2021-11-24 | Cytokinetics, Inc. | Methods of reducing decline in vital capacity |
| TW201927738A (zh) * | 2017-12-14 | 2019-07-16 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| TWI794369B (zh) * | 2017-12-14 | 2023-03-01 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| JP7592029B2 (ja) | 2019-05-28 | 2024-11-29 | マンカインド ファーマ リミテッド | ヤヌスキナーゼ１の阻害のための新規化合物 |
| KR20240024062A (ko) * | 2021-05-06 | 2024-02-23 | 엑스사이언티아 에이아이 리미티드 | Pkc-세타 조정제 |
| CN118702622A (zh) * | 2024-08-30 | 2024-09-27 | 阜新达得利化工股份有限公司 | 一种3-溴-2-氰基吡啶的制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206860D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| GB0212048D0 (en) * | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| AU2003294249A1 (en) | 2002-11-08 | 2004-06-03 | Trimeris, Inc. | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| US20060148805A1 (en) | 2003-07-01 | 2006-07-06 | Meng Hsin Chen | Opthalmic compositions for treating ocular hypertension |
| CA2550091A1 (en) | 2003-12-19 | 2005-07-07 | Elixir Pharmaceuticals, Inc. | Methods of treating a disorder |
| EP1715855A4 (en) | 2004-01-29 | 2010-06-16 | Elixir Pharmaceuticals Inc | ANTIVIRAL DRUGS |
| WO2005108374A1 (en) | 2004-04-29 | 2005-11-17 | Fmc Corporation | Insecticidal diazole and triazole derivatives |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| EP1959962A2 (en) * | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| EP2666777A1 (en) | 2006-08-02 | 2013-11-27 | Cytokinetics, Inc. | Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods |
| NZ576278A (en) | 2006-10-19 | 2011-12-22 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| WO2008075007A1 (en) * | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
| EP2139478A4 (en) * | 2007-03-30 | 2010-05-05 | Cytokinetics Inc | CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
| MX2010008518A (es) * | 2008-02-04 | 2010-11-10 | Cytokinetics Inc | Ciertas entidades quimicas, composiciones y metodos. |
| US7998976B2 (en) | 2008-02-04 | 2011-08-16 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| CN102264743B (zh) | 2008-11-25 | 2015-02-11 | 罗彻斯特大学 | Mlk抑制剂及其使用方法 |
-
2009
- 2009-02-02 MX MX2010008518A patent/MX2010008518A/es not_active Application Discontinuation
- 2009-02-02 KR KR1020107018611A patent/KR20100119773A/ko not_active Withdrawn
- 2009-02-02 EP EP09708594A patent/EP2244711A4/en not_active Withdrawn
- 2009-02-02 AU AU2009210787A patent/AU2009210787A1/en not_active Abandoned
- 2009-02-02 US US12/364,394 patent/US7989469B2/en not_active Expired - Fee Related
- 2009-02-02 CA CA2713864A patent/CA2713864A1/en not_active Abandoned
- 2009-02-02 JP JP2010545031A patent/JP2011510985A/ja not_active Withdrawn
- 2009-02-02 WO PCT/US2009/000686 patent/WO2009099594A1/en not_active Ceased
- 2009-02-02 BR BRPI0907502A patent/BRPI0907502A2/pt not_active Application Discontinuation
- 2009-02-02 CN CN2009801121602A patent/CN101983061A/zh active Pending
- 2009-02-02 EA EA201001224A patent/EA201001224A1/ru unknown
- 2009-02-03 TW TW098103382A patent/TW200946524A/zh unknown
- 2009-02-04 CL CL2009000246A patent/CL2009000246A1/es unknown
- 2009-02-04 AR ARP090100372A patent/AR072242A1/es unknown
-
2010
- 2010-08-02 IL IL207367A patent/IL207367A0/en unknown
- 2010-08-13 ZA ZA2010/05780A patent/ZA201005780B/en unknown
- 2010-08-27 EC EC2010010430A patent/ECSP10010430A/es unknown
- 2010-08-30 EC EC2010010432A patent/ECSP10010432A/es unknown
- 2010-08-30 CO CO10106625A patent/CO6290673A2/es not_active Application Discontinuation
-
2011
- 2011-06-21 US US13/165,281 patent/US20110312975A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009210787A1 (en) | 2009-08-13 |
| ECSP10010432A (es) | 2011-01-31 |
| EP2244711A4 (en) | 2011-08-24 |
| CN101983061A (zh) | 2011-03-02 |
| CO6290673A2 (es) | 2011-06-20 |
| CL2009000246A1 (es) | 2009-06-26 |
| AR072242A1 (es) | 2010-08-18 |
| EA201001224A1 (ru) | 2011-08-30 |
| US7989469B2 (en) | 2011-08-02 |
| KR20100119773A (ko) | 2010-11-10 |
| MX2010008518A (es) | 2010-11-10 |
| TW200946524A (en) | 2009-11-16 |
| WO2009099594A1 (en) | 2009-08-13 |
| US20090253737A1 (en) | 2009-10-08 |
| JP2011510985A (ja) | 2011-04-07 |
| CA2713864A1 (en) | 2009-08-13 |
| EP2244711A1 (en) | 2010-11-03 |
| US20110312975A1 (en) | 2011-12-22 |
| ECSP10010430A (es) | 2011-02-28 |
| IL207367A0 (en) | 2010-12-30 |
| ZA201005780B (en) | 2011-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0907502A2 (pt) | pelo menos um entidade química, composição, e, métodos para tratar um paciente tendo uma condição, para aumentar a função ou atividade do músculo esquelético, para aumentar a eficiência do músculo esquelético, parab aumentar o tempo da fadiga de fibra muscular esquelética rápida, para sensibilizar uma fibra muscular esquelética rápida para produzir força em resposta a baixas concentreações de íons cálcio e para aumentar o tempo de fadiga muscular esquelética | |
| AR109995A2 (es) | Método para inhibir la resorción ósea | |
| BR122020000059B8 (pt) | composição que compreende uma matriz biocompatível e um fator de crescimento derivado de plaqueta e kit | |
| PL381801A1 (pl) | Pochodne mocznika, kompozycje zawierające pochodne mocznika oraz zastosowanie pochodnych mocznika do wytwarzania leku do leczenia skurczowej niewydolności serca | |
| EA201000559A1 (ru) | Композиции и способы применения антител к склеростину | |
| BRPI0911176B8 (pt) | método de tratar uma composição de célula vermelha sanguínea, composição de célula vermelha sanguínea, e método de reduzir a desidratação em uma composição de célula vermelha sanguínea | |
| EA201170349A1 (ru) | Модуляторы mif | |
| UA99839C2 (ru) | Бензодиазепиноновые соединения, применяемые при лечении кожных состояний | |
| CY1114952T1 (el) | Ενεργοποιητες θειενο[2,3-b]πυριδινοδιονης της αμρκ και θεραπευτικες χρησεις αυτων | |
| AR080685A1 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| BRPI0618577A8 (pt) | Usos de rituximab | |
| BR112012008665A2 (pt) | tratamento de câncer | |
| BRPI0706676B8 (pt) | uso de uma solução aquosa com potencial de oxirredução | |
| BR112012024806A2 (pt) | membro de fixação arcado e implante intervertebral | |
| ATE308303T1 (de) | Verwendung von kreatin, kreatinin und/oder cyclokreatin zur stärkung und verbesserung der haarstruktur | |
| CL2009000309A1 (es) | Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2. | |
| EA201071146A1 (ru) | Способы диагностирования, предупреждения и лечения болезней, связанных с костной массой | |
| BRPI0612840A8 (pt) | Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções | |
| Zhao et al. | An embryonic myosin isoform enables stretch activation and cyclical power in Drosophila jump muscle | |
| DE602006006177D1 (de) | Biologisch absorbierbare füllstoffe bestehend aus phospholipidliposomen und hyaluronsäure und/oder derivaten davon | |
| BR112022003686A2 (pt) | Tratamento de sintomas induzidos pelo ciclo menstrual | |
| BR112013013112A2 (pt) | uso de uma composição tendo uma densidade de energia entre 0,9 e 1,5 kcal/ml, composição para uso no controle de níveis de colesterol e triglicérides em um paciente que apresenta diabetes tipo 2 | |
| BRPI1010941A2 (pt) | métodos para promover a formação de anel de dinamina e/ou a manutenção de anéis de dinamina em uma célula, para profilaxia ou tratamento de uma doença ou condição renal, e de disfunção dos podócitos, para induzir adesões focais e/ou citoesuqleto de actina em uma célula, e de triagem de uma agente de teste para uso como um estabilizador de anel de dinamina, estabilizador de anel de dinamina, e, uso de pelo menos um estabilizador de anel de dinamina | |
| BRPI0411429A (pt) | tratamento de sintomas associados com vaginose bacteriana | |
| ATE556134T1 (de) | Mesenchymstammzellen und verwendungendafür |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE US 61/026,067 DE 04/02/2008 REIVINDICADA NO PCT/US2009/000686 DE 02/02/2009 POR NAO CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI 2494 DE 23/10/2018 PARA APRESENTACAO DE DOCUMENTO DE CESSAO CORRETO. |
|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |